Insulin detemir: A historical perspective on a modern basal insulin analogue.

Luigi Meneghini, Andreas Liebl, Martin J. Abrahamson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.

Original languageEnglish (US)
JournalPrimary Care Diabetes
Volume4 Suppl 1
DOIs
StatePublished - Apr 2010

Fingerprint

Insulins
Weight Gain
Isophane Insulin
Insulin
Hypoglycemia
Type 2 Diabetes Mellitus
Blood Glucose
Fasting
Primary Health Care
Glucose
Insulin Detemir

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics

Cite this

Insulin detemir : A historical perspective on a modern basal insulin analogue. / Meneghini, Luigi; Liebl, Andreas; Abrahamson, Martin J.

In: Primary Care Diabetes, Vol. 4 Suppl 1, 04.2010.

Research output: Contribution to journalArticle

@article{828b23e5eb93407e8b12c428d466fd15,
title = "Insulin detemir: A historical perspective on a modern basal insulin analogue.",
abstract = "Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.",
author = "Luigi Meneghini and Andreas Liebl and Abrahamson, {Martin J.}",
year = "2010",
month = "4",
doi = "10.1016/S1751-9918(10)60007-1",
language = "English (US)",
volume = "4 Suppl 1",
journal = "Primary Care Diabetes",
issn = "1751-9918",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Insulin detemir

T2 - A historical perspective on a modern basal insulin analogue.

AU - Meneghini, Luigi

AU - Liebl, Andreas

AU - Abrahamson, Martin J.

PY - 2010/4

Y1 - 2010/4

N2 - Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.

AB - Insulin detemir provides prolonged, reproducible blood glucose reduction through a mechanism unique among basal insulins. It was originally studied clinically in predominantly basal + bolus regimens and found to be associated with a low risk of hypoglycaemia compared to insulin NPH, and reduced weight gain compared to other basal insulins. Insulin detemir has been increasingly studied in basal-only insulin regimens in type 2 diabetes, in which an understanding of how to optimize its use has been built incrementally. Glycaemic control and limitation of weight gain tend to be maximized by once-daily (evening) dosing, earlier initiation and careful titration to appropriate fasting glucose targets. 2010 Primary Care Diabetes Europe. Published by Elsevier Ltd.. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=77954930050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954930050&partnerID=8YFLogxK

U2 - 10.1016/S1751-9918(10)60007-1

DO - 10.1016/S1751-9918(10)60007-1

M3 - Article

C2 - 20394890

AN - SCOPUS:77954930050

VL - 4 Suppl 1

JO - Primary Care Diabetes

JF - Primary Care Diabetes

SN - 1751-9918

ER -